Michael A. Bookman

Oncology | Hematology Oncology

2238 Geary Blvd
2nd Floor
San Francisco, CA 94115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Gynecologic Cancer InterGroup code of conduct for diversity in gynecological cancer trials: a clinical guide from the Berlin Gynecologic Cancer InterGroup meeting.

Gynecologic Cancer InterGroup code of conduct for diversity in gynecological cancer trials: a clinical guide from the Berlin Gynecologic Cancer InterGroup meeting.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 15, 2026

Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting.

Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 13, 2026

Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.

Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.

Journal: Gynecologic oncology

Published: April 12, 2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Journal: The Lancet. Oncology

Published: February 24, 2026

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Journal: Gynecologic oncology

Published: December 07, 2025

Factors accounting for excess uterine cancer mortality among insured Black versus White patients treated within the same US health care system.

Factors accounting for excess uterine cancer mortality among insured Black versus White patients treated within the same US health care system.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 20, 2025

Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.

Clearing the Path for Immunologic Targeting of Gynecologic Clear Cell Carcinomas.

Journal: JAMA oncology

Published: July 03, 2025

Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.

Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 04, 2025

Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.

Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.

Journal: Gynecologic oncology

Published: February 27, 2025

Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial.

Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 04, 2025

Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.

Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.

Journal: Gynecologic oncology

Published: January 31, 2025

How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.

How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 04, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026